The winding road of cardiac regeneration—Stem cell omics in the spotlight

Cells

Volumn 7, Issue 12, 2018, Pages

  Micheu, Miruna Mihaela ^a   Scarlatescu, Alina Ioana ^a   Scafa Udriste, Alexandru ^a,b   Dorobantu, Maria ^a,b  

^a Clinic Emergency Hospital Bucharest   (Romania)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Cardiac regeneration; Cardioprotection; Omics data; Precision medicine; Stem cells

Indexed keywords

ANGIOPOIETIN 1; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 6; LERCANIDIPINE; LONG UNTRANSLATED RNA; MICRORNA; MICRORNA 126; MICRORNA 146A; MICRORNA 181B; MICRORNA 199A; MICRORNA 208; MICRORNA 21; MICRORNA 210; MICRORNA 22; MICRORNA 221; MICRORNA 24; MICRORNA 291; MICRORNA 294; MICRORNA 30B; MICRORNA 30C; S ADENOSYLMETHIONINE; SCATTER FACTOR; SOMATOMEDIN C RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN;

CARDIAC STEM CELL; CELL DIFFERENTIATION; CELL MIGRATION; CELL SURVIVAL; COPY NUMBER VARIATION; CYTOLOGY; DNA BINDING; DNA METHYLATION; EMBRYONIC STEM CELL; EPIGENETICS; GENE EXPRESSION; GENOMICS; GLYCOLYSIS; HEART FAILURE; HISTONE MODIFICATION; HYPOXIA; ISCHEMIC HEART DISEASE; MESENCHYMAL STEM CELL; METABOLISM; MORTALITY RATE; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PHENOTYPE; PLURIPOTENT STEM CELL; REGENERATIVE MEDICINE; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS; TRISOMY 12; TRISOMY 8;

EID: 85065567155     PISSN: None     EISSN: 20734409     Source Type: Journal    
DOI: 10.3390/cells7120255     Document Type: Review

References (186)

1. Nunez, G.A.; Sanz-Ruiz, R.; Fernandez, S.M.E.; Fernandez-Aviles, F. “Second-generation” stem cells for cardiac repair. World J. Stem Cell 2015, 7, 352–367.
2. Fernandez-Aviles, F.; Sanz-Ruiz, R.; Climent, A.M.; Badimon, L.; Bolli, R.; Charron, D.; Fuster, V.; Janssens, S.; Kastrup, J.; Kim, H.S.; et al. Global position paper on cardiovascular regenerative medicine. Eur. Heart J. 2017, 38, 2532–2546.
3. Micheu, M.M.; Dorobantu, M. Fifteen years of bone marrow mononuclear cell therapy in acute myocardial infarction. World J. Stem Cell 2017, 9, 68–76.
4. Dorobantu, M.; Popa-Fotea, N.M.; Popa, M.; Rusu, I.; Micheu, M.M. Pursuing meaningful end-points for stem cell therapy assessment in ischemic cardiac disease. World J. Stem Cell 2017, 9, 203–218.
5. Strauer, B.E.; Brehm, M.; Zeus, T.; Gattermann, N.; Hernandez, A.; Sorg, R.V.; Kogler, G.; Wernet, P. Intracoronary, human autologous stem cell transplantation for myocardial regeneration following myocardial infarction. Deut. Med. Wochenschr. 2001, 126, 932–938.
6. Assou, S.; Bouckenheimer, J.; De Vos, J. Concise Review: Assessing the Genome Integrity of Human Induced Pluripotent Stem Cells: What Quality Control Metrics? Stem Cells 2018, 36, 814–821.
7. Yoshihara, M.; Hayashizaki, Y.; Murakawa, Y. Genomic Instability of iPSCs: Challenges Towards Their Clinical Applications. Stem Cell Rev. 2017, 13, 7–16.
8. Taapken, S.M.; Nisler, B.S.; Newton, M.A.; Sampsell-Barron, T.L.; Leonhard, K.A.; McIntire, E.M.; Montgomery, K.D. Karotypic abnormalities in human induced pluripotent stem cells and embryonic stem cells. Nat. Biotechnol. 2011, 29, 313–314.
9. Mayshar, Y.; Ben-David, U.; Lavon, N.; Biancotti, J.C.; Yakir, B.; Clark, A.T.; Plath, K.; Lowry, W.E.; Benvenisty, N. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell 2010, 7, 521–531.
10. Rebuzzini, P.; Zuccotti, M.; Redi, C.A.; Garagna, S. Chromosomal Abnormalities in Embryonic and Somatic Stem Cells. Cytogenet. Genome Res. 2015, 147, 1–9.
11. Tosca, L.; Feraud, O.; Magniez, A.; Bas, C.; Griscelli, F.; Bennaceur-Griscelli, A.; Tachdjian, G. Genomic instability of human embryonic stem cell lines using different passaging culture methods. Mol. Cytogenet. 2015, 8, 30.
12. Nguyen, H.T.; Geens, M.; Mertzanidou, A.; Jacobs, K.; Heirman, C.; Breckpot, K.; Spits, C. Gain of 20q11.21 in human embryonic stem cells improves cell survival by increased expression of Bcl-xL. Mol. Hum. Reprod. 2014, 20, 168–177.
13. Lefort, N.; Feyeux, M.; Bas, C.; Feraud, O.; Bennaceur-Griscelli, A.; Tachdjian, G.; Peschanski, M.; Perrier, A.L. Human embryonic stem cells reveal recurrent genomic instability at 20q11.21. Nat. Biotechnol. 2008, 26, 1364–1366.
14. Spits, C.; Mateizel, I.; Geens, M.; Mertzanidou, A.; Staessen, C.; Vandeskelde, Y.; Van der Elst, J.; Liebaers, I.;, Sermon, K. Recurrent chromosomal abnormalities in human embryonic stem cells. Nat. Biotechnol. 2008, 26, 1361–1363.
15. Ben-David, U.; Mayshar, Y.; Benvenisty, N. Large-scale analysis reveals acquisition of lineage-specific chromosomal aberrations in human adult stem cells. Cell Stem Cell 2011, 9, 97–102.
16. Li, T.S.; Marban, E. Physiological levels of reactive oxygen species are required to maintain genomic stability in stem cells. Stem Cell. 2010, 28, 1178–1185.
17. Li, T.S.; Cheng, K.; Malliaras, K.; Matsushita, N.; Sun, B.; Marban, L.; Zhang, Y.; Marban, E. Expansion of human cardiac stem cells in physiological oxygen improves cell production efficiency and potency for myocardial repair. Cardiovasc. Res. 2011, 89, 157–165.
18. Oliveira, P.H.; da Silva, C.L.; Cabral, J.M. Concise review: Genomic instability in human stem cells: Current status and future challenges. Stem Cell. 2014, 32, 2824–2832.
19. Laurent, L.C.; Ulitsky, I.; Slavin, I.; Tran, H.; Schork, A.; Morey, R.; Lynch, C.; Harness, J.V.; Lee, S.; Barrero, M.J.; et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 2011, 8, 106–118.
20. Cai, J.; Miao, X.; Li, Y.; Smith, C.; Tsang, K.; Cheng, L.; Wang, Q.F. Whole-genome sequencing identifies genetic variances in culture-expanded human mesenchymal stem cells. Stem Cell Rep. 2014, 3, 227–233.
21. Kim, M.; Rhee, J.K.; Choi, H.; Kwon, A.; Kim, J.; Lee, G.D.; Jekarl, D.W.; Lee, S.; Kim, Y.; Kim, T.M. Passage-dependent accumulation of somatic mutations in mesenchymal stromal cells during in vitro culture revealed by whole genome sequencing. Sci. Rep. 2017, 7, 14508.
22. Wang, Y.; Zhang, Z.; Chi, Y.; Zhang, Q.; Xu, F.; Yang, Z.; Meng, L.; Yang, S.; Yan, S.; Mao, A.; et al. Long-term cultured mesenchymal stem cells frequently develop genomic mutations but do not undergo malignant transformation. Cell Death Dis. 2013, 4, e950.
23. Menasche, P.; Vanneaux, V.; Hagege, A.; Bel, A.; Cholley, B.; Cacciapuoti, I.; Parouchev, A.; Benhamouda, N.; Tachdjian, G.; Tosca, L.; et al. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: First clinical case report. Eur. Heart J. 2015, 36, 2011–2017.
24. Godini, R.; Lafta, H.Y.; Fallahi, H. Epigenetic modifications in the embryonic and induced pluripotent stem cells. Gene Expr. Patterns. 2018, 29, 1–9.
25. Dupont, C.; Armant, D.R.; Brenner, C.A. Epigenetics: Definition, mechanisms and clinical perspective. Semin. Reprod. Med. 2009, 27, 351–357.
26. Klungland, A.; Robertson, A.B. Oxidized C5-methyl cytosine bases in DNA: 5-Hydroxymethylcytosine; 5-formylcytosine; and 5-carboxycytosine. Free Radic. Biol. Med. 2017, 107, 62–68.
27. Bock, C.; Kiskinis, E.; Verstappen, G.; Gu, H.; Boulting, G.; Smith, Z.D.; Ziller, M.; Croft, G.F.; Amoroso, M.W.; Oakley, D.H.; et al. Reference Maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell 2011, 144, 439–452.
28. Ziller, M.J.; Muller, F.; Liao, J.; Zhang, Y.; Gu, H.; Bock, C.; Boyle, P.; Epstein, C.B.; Bernstein, B.E.; Lengauer, T.; et al. Genomic distribution and inter-sample variation of non-CpG methylation across human cell types. PLoS Genet. 2011, 7, e1002389.
29. Antonitsis, P.; Ioannidou-Papagiannaki, E.; Kaidoglou, A.; Charokopos, N.; Kalogeridis, A.; Kouzi-Koliakou, K.; Kyriakopoulou, I.; Klonizakis, I.; Papakonstantinou, C. Cardiomyogenic potential of human adult bone marrow mesenchymal stem cells in vitro. Thorac. Cardiovasc. Surg. 2008, 56, 77–82.
30. Ye, N.S.; Chen, J.; Luo, G.A.; Zhang, R.L.; Zhao, Y.F.; Wang, Y.M. Proteomic profiling of rat bone marrow mesenchymal stem cells induced by 5-azacytidine. Stem Cells Dev. 2006, 15, 665–676.
31. Antonitsis, P.; Ioannidou-Papagiannaki, E.; Kaidoglou, A.; Papakonstantinou, C. In vitro cardiomyogenic differentiation of adult human bone marrow mesenchymal stem cells. The role of 5-azacytidine. Int. Cardiovasc. Thorac. Surg. 2007, 6, 593–597.
32. Ye, N.S.; Zhang, R.L.; Zhao, Y.F.; Feng, X.; Wang, Y.M.; Luo, G.A. Effect of 5-azacytidine on the protein expression of porcine bone marrow mesenchymal stem cells in vitro. Genom. Proteom. Bioinform. 2006, 4, 18–25.
33. Martin-Rendon, E.; Sweeney, D.; Lu, F.; Girdlestone, J.; Navarrete, C.; Watt, S.M. 5-Azacytidine-treated human mesenchymal stem/progenitor cells derived from umbilical cord, cord blood and bone marrow do not generate cardiomyocytes in vitro at high frequencies. Vox Sang. 2008, 95, 137–148.
34. Liu, Y.; Song, J.; Liu, W.; Wan, Y.; Chen, X.; Hu, C. Growth and differentiation of rat bone marrow stromal cells: Does 5-azacytidine trigger their cardiomyogenic differentiation? Cardiovasc. Res. 2003, 58, 460–468.
35. Rosca, A.M.; Burlacu, A. Effect of 5-azacytidine: Evidence for alteration of the multipotent ability of mesenchymal stem cells. Stem Cells Dev. 2011, 20, 1213–1221.
36. Naeem, N.; Haneef, K.; Kabir, N.; Iqbal, H.; Jamall, S.; Salim, A. DNA methylation inhibitors, 5-azacytidine and zebularine potentiate the transdifferentiation of rat bone marrow mesenchymal stem cells into cardiomyocytes. Cardiovasc. Ther. 2013, 31, 201–209.
37. Horrillo, A.; Pezzolla, D.; Fraga, M.F.; Aguilera, Y.; Salguero-Aranda, C.; Tejedo, J.R.; Martin, F.; Bedoya, F.J.; Soria, B.; Hmadcha, A. Zebularine regulates early stages of mESC differentiation: Effect on cardiac commitment. Cell Death Dis. 2013, 4, e570.
38. Berdasco, M.; Esteller, M. DNA methylation in stem cell renewal and multipotency. Stem Cell Res. Ther. 2011, 2, 42.
39. Shi, G.; Jin, Y. Role of Oct4 in maintaining and regaining stem cell pluripotency. Stem Cell Res. Ther. 2010, 1, 39.
40. Lagarkova, M.A.; Volchkov, P.Y.; Lyakisheva, A.V.; Philonenko, E.S.; Kiselev, S.L. Diverse epigenetic profile of novel human embryonic stem cell lines. Cell Cycle 2006, 5, 416–420.
41. Fouse, S.D.; Shen, Y.; Pellegrini, M.; Cole, S.; Meissner, A.; Van Neste, L.; Jaenisch, R.; Fan, G. Promoter CpG methylation contributes to ES cell gene regulation in parallel with Oct4/Nanog, PcG complex, and histone H3 K4/K27 trimethylation. Cell Stem Cell 2008, 2, 160–169.
42. Barrand, S.; Collas, P. Chromatin states of core pluripotency-associated genes in pluripotent, multipotent and differentiated cells. Biochem. Biophys. Res. Commun. 2010, 391, 762–767.
43. Yang, J.Y.; Wang, Q.; Wang, W.; Zeng, L.F. Histone deacetylases and cardiovascular cell lineage commitment. World J. Stem Cells 2015, 7, 852–858.
44. Zeng, L.; Xiao, Q.; Margariti, A.; Zhang, Z.; Zampetaki, A.; Patel, S.; Capogrossi, M.C.; Hu, Y.; Xu, Q. HDAC3 is crucial in shear-and VEGF-induced stem cell differentiation toward endothelial cells. J. Cell Biol. 2006, 174, 1059–1069.
45. Dovey, O.M.; Foster, C.T.; Cowley, S.M. Histone deacetylase 1 (HDAC1), but not HDAC2, controls embryonic stem cell differentiation. Proc. Natl. Acad. Sci. USA 2010, 107, 8242–8247.
46. Lu, D.F.; Yao, Y.; Su, Z.Z.; Zeng, Z.H.; Xing, X.W.; He, Z.Y.; Zhang, C. Downregulation of HDAC1 is involved in the cardiomyocyte differentiation from mesenchymal stem cells in a myocardial microenvironment. PLoS ONE 2014, 9, e93222.
47. Lu, D.F.; Wang, Y.; Su, Z.Z.; Zeng, Z.H.; Xing, X.W.; He, Z.Y.; Zhang, C. Knockdown of the HDAC1 promotes the directed differentiation of bone mesenchymal stem cells into cardiomyocytes. PLoS ONE 2014, 9, e92179.
48. Liu, Z.; Li, T.; Liu, Y.; Jia, Z.; Li, Y.; Zhang, C.; Chen, P.; Ma, K.; Affara, N.; Zhou, C. WNT signaling promotes Nkx2.5 expression and early cardiomyogenesis via downregulation of Hdac1. Biochim. Biophys. Acta 2009, 1793, 300–311.
49. Hoxha, E.; Lambers, E.; Wasserstrom, J.A.; Mackie, A.; Ramirez, V.; Abramova, T.; Verma, S.K.; Krishnamurthy, P.; Kishore, R. Elucidation of a novel pathway through which HDAC1 controls cardiomyocyte differentiation through expression of SOX-17 and BMP2. PLoS ONE 2012, 7, e45046.
50. Hoxha, E.; Lambers, E.; Xie, H.; De Andrade, A.; Krishnamurthy, P.; Wasserstrom, J.A.; Ramirez, V.; Thal, M.; Verma, S.K.; Soares, M.B.; et al. Histone deacetylase 1 deficiency impairs differentiation and electrophysiological properties of cardiomyocytes derived from induced pluripotent cells. Stem Cell. 2012, 30, 2412–2422.
51. Hasin, Y.; Seldin, M.; Lusis, A. Multi-omics approaches to disease. Genome Biol. 2017, 18, 83.
52. Billing, A.M.; Ben Hamidane, H.; Dib, S.S.; Cotton, R.J.; Bhagwat, A.M.; Kumar, P.; Hayat, S.; Yousri, N.A.; Goswami, N.; Suhre, K.; et al. Comprehensive transcriptomic and proteomic characterization of human mesenchymal stem cells reveals source specific cellular markers. Sci. Rep. 2016, 6, 21507.
53. Medina, R.J.; Barber, C.L.; Sabatier, F.; Dignat-George, F.; Melero-Martin, J.M.; Khosrotehrani, K.; Ohneda, O.; Randi, A.M.; Chan, J.K.Y.; Yamaguchi, T.; et al. Endothelial Progenitors: A Consensus Statement on Nomenclature. Stem Cells Transl. Med. 2017, 6, 1316–1320.
54. Medina, R.J.; O’Neill, C.L.; Sweeney, M.; Guduric-Fuchs, J.; Gardiner, T.A.; Simpson, D.A.; Stitt, A.W. Molecular analysis of endothelial progenitor cell (EPC) subtypes reveals two distinct cell populations with different identities. BMC Med. Genom. 2010, 3, 18.
55. Steinle, H.; Behring, A.; Schlensak, C.; Wendel, H.P.; Avci-Adali, M. Concise Review: Application of In Vitro Transcribed Messenger RNA for Cellular Engineering and Reprogramming: Progress and Challenges. Stem Cell. 2017, 35, 68–79.
56. Zangi, L.; Lui, K.O.; von Gise, A.; Ma, Q.; Ebina, W.; Ptaszek, L.M.; Spater, D.; Xu, H.; Tabebordbar, M.; Gorbatov, R.; et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat. Biotechnol. 2013, 31, 898–907.
57. Seeger, F.H.; Zeiher, A.M.; Dimmeler, S. MicroRNAs in stem cell function and regenerative therapy of the heart. Arterioscler. Thromb. Vasc. Biol. 2013, 33, 1739–1746.
58. Kuppusamy, K.T.; Sperber, H.; Ruohola-Baker, H. MicroRNA regulation and role in stem cell maintenance, cardiac differentiation and hypertrophy. Curr. Mol. Med. 2013, 13, 757–764.
59. Kane, N.M.; Thrasher, A.J.; Angelini, G.D.; Emanueli, C. Concise review: MicroRNAs as modulators of stem cells and angiogenesis. Stem Cell. 2014, 32, 1059–1066.
60. Li, B.; Meng, X.; Zhang, L. microRNAs and cardiac stem cells in heart development and disease. Drug Discov. Today. 2018 (in press)
61. Prathipati, P.; Nandi, S.S.; Mishra, P.K. Stem Cell-Derived Exosomes, Autophagy, Extracellular Matrix Turnover, and miRNAs in Cardiac Regeneration during Stem Cell Therapy. Stem Cell Rev. 2017, 13, 79–91.
62. Wojciechowska, A.; Braniewska, A.; Kozar-Kaminska, K. MicroRNA in cardiovascular biology and disease. Adv. Clin. Exp. Med. 2017, 26, 865–874.
63. Jakob, P.; Doerries, C.; Briand, S.; Mocharla, P.; Krankel, N.; Besler, C.; Mueller, M.; Manes, C.; Templin, C.; Baltes, C.; et al. Loss of angiomiR-126 and 130a in angiogenic early outgrowth cells from patients with chronic heart failure: Role for impaired in vivo neovascularization and cardiac repair capacity. Circulation 2012, 126, 2962–2975.
64. Chen, J.J.; Zhou, S.H. Mesenchymal stem cells overexpressing MiR-126 enhance ischemic angiogenesis via the AKT/ERK-related pathway. Cardiol. J. 2011, 18, 675–681.
65. Huang, F.; Zhu, X.; Hu, X.Q.; Fang, Z.F.; Tang, L.; Lu, X.L.; Zhou, S.H. Mesenchymal stem cells modified with miR-126 release angiogenic factors and activate Notch ligand Delta-like-4, enhancing ischemic angiogenesis and cell survival. Int. J. Mol. Med. 2013, 31, 484–492.
66. Wang, S.; Aurora, A.B.; Johnson, B.A.; Qi, X.; McAnally, J.; Hill, J.A.; Richardson, J.A.; Bassel-Duby, R.; Olson, E.N. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell 2008, 15, 261–271.
67. Hu, S.; Huang, M.; Nguyen, P.K.; Gong, Y.; Li, Z.; Jia, F.; Lan, F.; Liu, J.; Nag, D.; Robbins, R.C.; et al. Novel microRNA prosurvival cocktail for improving engraftment and function of cardiac progenitor cell transplantation. Circulation 2011, 124 (Suppl. 11), S27–S34.
68. Choong, O.K.; Lee, D.S.; Chen, C.Y.; Hsieh, P.C. The roles of non-coding RNAs in cardiac regenerative medicine. Non-Coding RNA Res. 2017, 2, 100–110.
69. Gu, G.L.; Xu, X.L.; Sun, X.T.; Zhang, J.; Guo, C.F.; Wang, C.S.; Sun, B.; Guo, G.L.; Ma, K.; Huang, Y.Y.; et al. Cardioprotective Effect of MicroRNA-21 in Murine Myocardial Infarction. Cardiovasc Ther. 2015, 33, 109– 117.
70. Gupta, S.K.; Itagaki, R.; Zheng, X.; Batkai, S.; Thum, S.; Ahmad, F.; Van Aelst, L.N.; Sharma, A.; Piccoli, M.T.;, Weinberger, F.; et al. miR-21 promotes fibrosis in an acute cardiac allograft transplantation model. Cardiovasc Res. 2016, 110, 215–226.
71. Glass, C.; Singla, D.K. MicroRNA-1 transfected embryonic stem cells enhance cardiac myocyte differentiation and inhibit apoptosis by modulating the PTEN/Akt pathway in the infarcted heart. Am. J. Physiol. Heart Circ. Physiol. 2011, 301, H2038–H2049.
72. Ivey, K.N.; Muth, A.; Arnold, J.; King, F.W.; Yeh, R.F.; Fish, J.E.; Hsiao, E.C.; Schwartz, R.J.; Conklin, B.R.; Bernstein, H.S.; et al. MicroRNA regulation of cell lineages in mouse and human embryonic stem cells. Cell Stem Cell 2008, 2, 219–229.
73. Wilson, K.D.; Hu, S.; Venkatasubrahmanyam, S.; Fu, J.D.; Sun, N.; Abilez, O.J.; Baugh, J.J.; Jia, F.; Ghosh, Z.; Li, R.A.; et al. Dynamic microRNA expression programs during cardiac differentiation of human embryonic stem cells: Role for miR-499. Circ. Cardiovasc. Genet. 2010, 3, 426–435.
74. Sluijter, J.P.; van Mil, A.; van Vliet, P.; Metz, C.H.; Liu, J.; Doevendans, P.A.; Goumans, M.J. MicroRNA-1 and-499 Regulate Differentiation and Proliferation in Human-Derived Cardiomyocyte Progenitor Cells. Arteriosc. Throm. Vasc. Biol. 2010, 30, 859–868.
75. Eulalio, A.; Mano, M.; Dal Ferro, M.; Zentilin, L.; Sinagra, G.; Zacchigna, S.; Giacca, M. Functional screening identifies miRNAs inducing cardiac regeneration. Nature 2012, 492, 376–381.
76. Jayawardena, T.M.; Egemnazarov, B.; Finch, E.A.; Zhang, L.; Payne, J.A.; Pandya, K.; Zhang, Z.; Rosenberg, P.; Mirotsou, M.; Dzau, V.J. MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. Circ. Res. 2012, 110, 1465–1473.
77. Flynn, R.A.; Chang, H.Y. Long noncoding RNAs in cell-fate programming and reprogramming. Cell Stem Cell 2014, 14, 752–761.
78. Di Mauro, V.; Barandalla-Sobrados, M.; Catalucci, D. The noncoding-RNA landscape in cardiovascular health and disease. Non. Coding RNA Res. 2018, 3, 12–19.
79. Klattenhoff, C.A.; Scheuermann, J.C.; Surface, L.E.; Bradley, R.K.; Fields, P.A.; Steinhauser, M.L.; Ding, H.; Butty, V.L.; Torrey, L.; Haas, S.; et al. Braveheart, a long noncoding RNA required for cardiovascular lineage commitment. Cell 2013, 152, 570–583.
80. Ounzain, S.; Micheletti, R.; Arnan, C.; Plaisance, I.; Cecchi, D.; Schroen, B.; Reverter, F.; Alexanian, M.; Gonzales, C.; Ng, S.Y.; et al. CARMEN, a human super enhancer-associated long noncoding RNA controlling cardiac specification, differentiation and homeostasis. J. Mol. Cell. Cardiol. 2015, 89, 98–112.
81. Loewer, S.; Cabili, M.N.; Guttman, M.; Loh, Y.H.; Thomas, K.; Park, I.H.; Garber, M.; Curran, M.; Onder, T.; Agarwal, S.; et al. Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Nat. Genet. 2010, 42, 1113–1117.
82. Shi, B.; Wang, Y.; Zhao, R.; Long, X.; Deng, W.; Wang, Z. Bone marrow mesenchymal stem cell-derived exosomal miR-21 protects C-kit+ cardiac stem cells from oxidative injury through the PTEN/PI3K/Akt axis. PLoS ONE 2018, 13, e0191616.
83. Zamani, P.; Fereydouni, N.; Butler, A.E.; Navashenaq, J.G.; Sahebkar, A. The therapeutic and diagnostic role of exosomes in cardiovascular diseases. Trends Cardiovasc Med. 2018, in press.
84. Feng, Y.; Huang, W.; Wani, M.; Yu, X.; Ashraf, M. Ischemic preconditioning potentiates the protective effect of stem cells through secretion of exosomes by targeting Mecp2 via miR-22. PLoS ONE 2014, 9, e88685.
85. Gong, M.; Yu, B.; Wang, J.; Wang, Y.; Liu, M.; Paul, C.; Millard, R.W.; Xiao, D.S.; Ashraf, M.; Xu, M. Mesenchymal stem cells release exosomes that transfer miRNAs to endothelial cells and promote angiogenesis. Oncotarget 2017, 8, 45200–45212.
86. de Couto, G.; Gallet, R.; Cambier, L.; Jaghatspanyan, E.; Makkar, N.; Dawkins, J.F.; Berman, B.P.; Marban, E. Exosomal MicroRNA Transfer into Macrophages Mediates Cellular Postconditioning. Circulation 2017, 136, 200–214.
87. Ibrahim, A.G.; Cheng, K.; Marban, E. Exosomes as critical agents of cardiac regeneration triggered by cell therapy. Stem Cell Rep. 2014, 2, 606–619.
88. Wang, X.; Ha, T.; Liu, L.; Zou, J.; Zhang, X.; Kalbfleisch, J.; Gao, X.; Williams, D.; Li, C. Increased expression of microRNA-146a decreases myocardial ischaemia/reperfusion injury. Cardiovasc Res. 2013, 97, 432–442.
89. Liu, J.; Wang, Y.; Cui, J.; Sun, M.; Pu, Z.; Wang, C.; Du, W.; Liu, X.; Wu, J.; Hou, J. et al. miR199a-3p regulates P53 by targeting CABLES1 in mouse cardiac c-kit(+) cells to promote proliferation and inhibit apoptosis through a negative feedback loop. Stem Cell Res. Ther. 2017, 8, 127.
90. Lee, S.; Yu, K.R.; Ryu, Y.S.; Oh, Y.S.; Hong, I.S.; Kim, H.S.; Lee, J.Y.; Kim, S.; Seo, K.W.; Kang, K.S. miR-543 and miR-590-3p regulate human mesenchymal stem cell aging via direct targeting of AIMP3/p18. Age 2014, 36, 9724.
91. Kim, H.W.; Haider, H.K.; Jiang, S.; Ashraf, M. Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2. J. Biol. Chem. 2009, 284, 33161–33168.
92. Khan, M.; Nickoloff, E.; Abramova, T.; Johnson, J.; Verma, S.K.; Krishnamurthy, P.; Mackie, A.R.; Vaughan, E.; Garikipati, V.N.; Benedict, C.; et al. Embryonic stem cell-derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction. Circ. Res. 2015, 117, 52–64.
93. Wu, F.; Yang, Z.; Li, G. Role of specific microRNAs for endothelial function and angiogenesis. Biochem Biophys. Res. Commun. 2009, 386, 549–553.
94. Hou, J.; Long, H.; Zhou, C.; Zheng, S.; Wu, H.; Guo, T.; Wu, Q., Zhong, T.; Wang, T. Long noncoding RNA Braveheart promotes cardiogenic differentiation of mesenchymal stem cells in vitro. Stem Cell Res. Ther. 2017, 8, 4.
95. Wang, Y.; Xu, Z.; Jiang, J.; Xu, C.; Kang, J.; Xiao, L.; Wu, M.; Xiong, J.; Guo, X., Liu, H. Endogenous miRNA sponge lincRNA-RoR regulates Oct4, Nanog, and Sox2 in human embryonic stem cell self-renewal. Dev. Cell. 2013, 25, 69–80.
96. Wyles, S.P.; Faustino, R.S.; Li, X.; Terzic, A.; Nelson, T.J. Systems-based technologies in profiling the stem cell molecular framework for cardioregenerative medicine. Stem Cell Rev. 2015, 11, 501–510.
97. Prudhomme, W.; Daley, G.Q.; Zandstra, P.; Lauffenburger, D.A. Multivariate proteomic analysis of murine embryonic stem cell self-renewal versus differentiation signaling. Proc. Natl. Acad. Sci. USA 2004, 101, 2900– 2905.
98. Abazova, N.; Krijgsveld, J. Advances in stem cell proteomics. Curr. Opin. Genet. Dev. 2017, 46, 149–155.
99. Kim, M.S.; Pinto, S.M.; Getnet, D.; Nirujogi, R.S.; Manda, S.S.; Chaerkady, R.; Madugundu, A.K.; Kelkar, D.S.; Isserlin, R.; Jain, S.; et al. A draft map of the human proteome. Nature 2014, 509, 575–581.
100. Wilhelm, M.; Schlegl, J.; Hahne, H.; Gholami, A.M.; Lieberenz, M.; Savitski, M.M.; Ziegler, E.; Butzmann, L.; Gessulat, S.; Marx, H.; et al. Mass-spectrometry-based draft of the human proteome. Nature 2014, 509, 582–587.
101. Tao, Z.H.; Han, Z.C.; Li, Z. Proangiogenic Features of Mesenchymal Stem Cells and Their Therapeutic Applications. Stem Cell. Int. 2016, doi:10.1155/2016/1314709.
102. Pankajakshan, D.; Agrawal, D.K. Mesenchymal Stem Cell Paracrine Factors in Vascular Repair and Regeneration. J. Biomed. Technol. Res. 2014, 1, doi: 10.19104/jbtr.2014.107.
103. Hastings, C.L.; Roche, E.T.; Ruiz-Hernandez, E.; Schenke-Layland, K.; Walsh, C.J.; Duffy, G.P. Drug and cell delivery for cardiac regeneration. Adv. Drug Deliv. Rev. 2015, 84, 85–106.
104. Ge, Q.; Zhang, H.; Hou, J.; Wan, L.; Cheng, W.; Wang, X.; Dong, D.; Chen, C.; Xia, J.; Guo, J.; et al. VEGF secreted by mesenchymal stem cells mediates the differentiation of endothelial progenitor cells into endothelial cells via paracrine mechanisms. Mol. Med. Rep. 2018, 17, 1667–1675.
105. Stastna, M.; Abraham, M.R.; Van Eyk, J.E. Cardiac stem/progenitor cells, secreted proteins, and proteomics. FEBS Lett. 2009, 583, 1800–1807.
106. Razban, V.; Lotfi, A.S.; Soleimani, M.; Ahmadi, H.; Massumi, M.; Khajeh, S.; Ghaedi, M.; Arjmand, S.; Najavand, S.; Khoshdel, A. HIF-1alpha Overexpression Induces Angiogenesis in Mesenchymal Stem Cells. Bio. Res. open access. 2012, 1, 174–183.
107. Urbich, C.; Aicher, A.; Heeschen, C.; Dernbach, E.; Hofmann, W.K.; Zeiher, A.M.; Dimmeler, S. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J. Mol. Cell Cardiol. 2005, 39, 733–742.
108. Bartunek, J.; Behfar, A.; Dolatabadi, D.; Vanderheyden, M.; Ostojic, M.; Dens, J.; El Nakadi, B.; Banovic, M.; Beleslin, B.; Vrolix, M.; et al. Cardiopoietic stem cell therapy in heart failure: The C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J. Am. Coll Cardiol. 2013, 61, 2329–2338.
109. Bartunek, J.; Terzic, A.; Davison, B.A.; Filippatos, G.S.; Radovanovic, S.; Beleslin, B.; Merkely, B.; Musialek, P.; Wojakowski, W.; Andreka, P. et al. Cardiopoietic cell therapy for advanced ischaemic heart failure: Results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. Eur. Heart J. 2017, 38, 648–660.
110. Chung, E.S.; Miller, L.; Patel, A.N.; Anderson, R.D.; Mendelsohn, F.O.; Traverse, J.; Silver, K.H.; Shin, J.; Ewald, G.; Farr, M.J. et al. Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: The STOP-HF randomized Phase II trial. Eur. Heart J. 2015, 36, 2228–2238.
111. Oliveira, M.S.; Saldanha-Araujo, F.; Goes, A.M.; Costa, F.F.; de Carvalho, J.L. Stem cells in cardiovascular diseases: Turning bad days into good ones. Drug Dis. Today 2017, 22, 1730–1739.113.
112. Abdelwahid, E.; Kalvelyte, A.; Stulpinas, A.; de Carvalho, K.A.; Guarita-Souza, L.C.; Foldes, G. Stem cell death and survival in heart regeneration and repair. Apoptosis 2016, 21, 252–268.
113. Li, L.; Chen, X.; Wang, W.E.; Zeng, C. How to Improve the Survival of Transplanted Mesenchymal Stem Cell in Ischemic Heart? Stem Cell. Int. 2016, 2016, 9682757.
114. Der Sarkissian, S.; Levesque, T.; Noiseux, N. Optimizing stem cells for cardiac repair: Current status and new frontiers in regenerative cardiology. World J. Stem Cell. 2017, 9, 9–25.
115. Matsumoto, R.; Omura, T.; Yoshiyama, M.; Hayashi, T.; Inamoto, S.; Koh, K.R.; Ohta, K.; Izumi, Y.; Nakamura, Y.; Akioka, K.; et al. Vascular endothelial growth factor-expressing mesenchymal stem cell transplantation for the treatment of acute myocardial infarction. Arteriosc. Throm. Vascul. Biol. 2005, 25, 1168–1173.
116. Yi, F.; Guo, W.Y.; Lu, A.L.; Wang, H.C.; Li, H.; Li, W.J.; Liu, B.; Zhang, D.X.; Luan, R.H.; Cheng, H.X.; et al. Vascular endothelial growth factor expressing mesenchymal stem cells improves cardiac function in chronic myocardial infarction in pigs. Chin. Med. J. 2006, 119, 1664–1668.
117. Mangi, A.A.; Noiseux, N.; Kong, D.; He, H.; Rezvani, M.; Ingwall, J.S.; Dzau, V.J. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat. Med. 2003, 9, 1195– 1201.
118. Noiseux, N.; Gnecchi, M.; Lopez-Ilasaca, M.; Zhang, L.; Solomon, S.D.; Deb, A.; Dzau, V.J.; Pratt, R.E. Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol. Ther. J. Am. Soc. Gene Ther. 2006, 14, 840–850.
119. Gnecchi, M.; He, H.; Noiseux, N.; Liang, O.D.; Zhang, L.; Morello, F.; Mu, H.; Melo, L.G.; Pratt, R.E.; Ingwall, J.S.; et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J. 2006, 20, 661–669.
120. Jiang, S.; Haider, H.; Idris, N.M.; Salim, A.; Ashraf, M. Supportive interaction between cell survival signaling and angiocompetent factors enhances donor cell survival and promotes angiomyogenesis for cardiac repair. Circ. Res. 2006, 99, 776–784.
121. Chao, J.; Bledsoe, G.; Chao, L. Kallikrein-kinin in stem cell therapy. World J. Stem Cells 2014, 6, 448–457.
122. Devetzi, M.; Goulielmaki, M.; Khoury, N.; Spandidos, D.A.; Sotiropoulou, G.; Christodoulou, I.; Zoumpourlis, V. Genetically modified stem cells in treatment of human diseases: Tissue kallikrein (KLK1) based targeted therapy (Review). Int. J. Mol. Med. 2018, 41, 1177–1186.
123. Yin, H.; Chao, L.; Chao, J. Nitric oxide mediates cardiac protection of tissue kallikrein by reducing inflammation and ventricular remodeling after myocardial ischemia/reperfusion. Life Sci. 2008, 82, 156–165.
124. Westermann, D.; Schultheiss, H.P.; Tschope, C. New perspective on the tissue kallikrein-kinin system in myocardial infarction: Role of angiogenesis and cardiac regeneration. Int. Immunopharmacol. 2008, 8, 148– 154.
125. Yao, Y.Y.; Yin, H.; Shen, B.; Smith, R.S., Jr.; Liu, Y.; Gao, L.; Chao, L.; Chao, J. Tissue kallikrein promotes neovascularization and improves cardiac function by the Akt-glycogen synthase kinase-3beta pathway. Cardiovasc. Res. 2008, 80, 354–364.
126. Yin, H.; Chao, L.; Chao, J. Kallikrein/kinin protects against myocardial apoptosis after ischemia/reperfusion via Akt-glycogen synthase kinase-3 and Akt-Bad.14-3-3 signaling pathways. J. Biol. Chem. 2005, 280, 8022– 8030.
127. Schumann, G.B.; Crisman, L.G. Cerebrospinal fluid cytopathology. Clin. Lab. Med. 1985, 5, 275–302.
128. Spillmann, F.; Graiani, G.; Van Linthout, S.; Meloni, M.; Campesi, I.; Lagrasta, C.; Westermann, D.; Tschope, C.; Quaini, F.; Emanueli, C.; et al. Regional and global protective effects of tissue kallikrein gene delivery to the peri-infarct myocardium. Regen. Med. 2006, 1, 235–254.
129. Gao, L.; Bledsoe, G.; Yin, H.; Shen, B.; Chao, L.; Chao, J. Tissue kallikrein-modified mesenchymal stem cells provide enhanced protection against ischemic cardiac injury after myocardial infarction. Circ. J. 2013, 77, 2134–2144.
130. Duan, H.F.; Wu, C.T.; Wu, D.L.; Lu, Y.; Liu, H.J.; Ha, X.Q.; Zhang, Q.W.; Wang, H.; Jia, X.X.; Wang, L.S. Treatment of myocardial ischemia with bone marrow-derived mesenchymal stem cells overexpressing hepatocyte growth factor. Mol. Ther. J. Am. Soc. Gene Ther. 2003, 8, 467–474.
131. Song, H.; Kwon, K.; Lim, S.; Kang, S.M.; Ko, Y.G.; Xu, Z.; Chung, J.H.; Kim, B.S.; Lee, H.; Joung, B.; et al. Transfection of mesenchymal stem cells with the FGF-2 gene improves their survival under hypoxic conditions. Mol. Cell. 2005, 19, 402–407.
132. Haider, H.; Jiang, S.; Idris, N.M.; Ashraf, M. IGF-1-overexpressing mesenchymal stem cells accelerate bone marrow stem cell mobilization via paracrine activation of SDF-1alpha/CXCR4 signaling to promote myocardial repair. Circ. Res. 2008, 103, 1300–1308.
133. Song, S.W.; Chang, W.; Song, B.W.; Song, H.; Lim, S.; Kim, H.J.; Cha, M.J.; Choi, E.; Im, S.H.; Chang, B.C.; et al. Integrin-linked kinase is required in hypoxic mesenchymal stem cells for strengthening cell adhesion to ischemic myocardium. Stem Cell. 2009, 27, 1358–1365.
134. Tang, J.; Wang, J.; Guo, L.; Kong, X.; Yang, J.; Zheng, F.; Zhang, L.; Huang, Y.; et al. Mesenchymal stem cells modified with stromal cell-derived factor 1 alpha improve cardiac remodeling via paracrine activation of hepatocyte growth factor in a rat model of myocardial infarction. Mol. Cell. 2010, 29, 9–19.
135. Bao, C.; Guo, J.; Zheng, M.; Chen, Y.; Lin, G.; Hu, M. Enhancement of the survival of engrafted mesenchymal stem cells in the ischemic heart by TNFR gene transfection. Biochemistry and cell biology. Biochem. Cell Biol. 2010, 88, 629–634.
136. Tang, Y.L.; Tang, Y.; Zhang, Y.C.; Qian, K.; Shen, L.; Phillips, M.I. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J. Am. Coll. Cardiol. 2005, 46, 1339–1350.
137. Yao, Y.; Sheng, Z.; Li, Y.; Yan, F.; Fu, C.; Li, Y.; Ma, G.; Liu, N.; Chao, J.; Chao, L. Tissue kallikrein promotes cardiac neovascularization by enhancing endothelial progenitor cell functional capacity. Hum. Gene Ther. 2012, 23, 859–870.
138. Yao, Y.; Sheng, Z.; Li, Y.; Fu, C.; Ma, G.; Liu, N.; Chao, J.; Chao, L. Tissue kallikrein-modified human endothelial progenitor cell implantation improves cardiac function via enhanced activation of akt and increased angiogenesis. Lab. Investig. 2013, 93, 577–591.
139. Sen, S.; Merchan, J.; Dean, J.; Ii, M.; Gavin, M.; Silver, M.; Tkebuchava, T.; Yoon, Y.S.; Rasko, J.E.; Aikawa, R. Autologous transplantation of endothelial progenitor cells genetically modified by adeno-associated viral vector delivering insulin-like growth factor-1 gene after myocardial infarction. Hum. Gene Ther. 2010, 21, 1327–1334.
140. Monsanto, M.M.; White, K.S.; Kim, T.; Wang, B.J.; Fisher, K.; Ilves, K.; Khalafalla, F.G.; Casillas, A.; Broughton, K.; Mohsin, S.; et al. Concurrent Isolation of 3 Distinct Cardiac Stem Cell Populations from a Single Human Heart Biopsy. Circ. Res. 2017, 121, 113–124.
141. Nadal-Ginard, B.; Ellison, G.M.; Torella, D. The cardiac stem cell compartment is indispensable for myocardial cell homeostasis, repair and regeneration in the adult. Stem Cell Res. 2014, 13, 615–630.
142. Messina, E.; De Angelis, L.; Frati, G.; Morrone, S.; Chimenti, S.; Fiordaliso, F.; Salio, M.; Battaglia, M.; Latronico, M.V.; Coletta, M.; et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ. Res. 2004, 95, 911–921.
143. Beltrami, A.P.; Barlucchi, L.; Torella, D.; Baker, M.; Limana, F.; Chimenti, S.; Kasahara, H.; Rota, M.; Musso, E.; Urbanek, K.; et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003, 114, 763–776.
144. Molgat, A.S.; Tilokee, E.L.; Rafatian, G.; Vulesevic, B.; Ruel, M.; Milne, R.; Suuronen, E.J.; Davis, D.R. Hyperglycemia inhibits cardiac stem cell-mediated cardiac repair and angiogenic capacity. Circulation 2014, 130 (Suppl 1), S70–S76.
145. Hsiao, L.C.; Perbellini, F.; Gomes, R.S.; Tan, J.J.; Vieira, S.; Faggian, G.; Clarke, K.; Carr, C.A. Murine cardiosphere-derived cells are impaired by age but not by cardiac dystrophic dysfunction. Stem Cells Dev. 2014, 23, 1027–1036.
146. Olivieri, F.; Recchioni, R.; Marcheselli, F.; Abbatecola, A.M.; Santini, G.; Borghetti, G.; Antonicelli, R.; Procopio, A.D. Cellular senescence in cardiovascular diseases: Potential age-related mechanisms and implications for treatment. Curr. Pharm. Des. 2013, 19, 1710–1719.
147. Jackson, R.; Tilokee, E.L.; Latham, N.; Mount, S.; Rafatian, G.; Strydhorst, J.; Ye, B.; Boodhwani, M.; Chan, V.; Ruel, M.; et al. Paracrine Engineering of Human Cardiac Stem Cells with Insulin-Like Growth Factor 1 Enhances Myocardial Repair. J. Am. Heart Assoc. 2015, 4, e002104.
148. Muraski, J.A.; Rota, M.; Misao, Y.; Fransioli, J.; Cottage, C.; Gude, N.; Esposito, G.; Delucchi, F.; Arcarese, M.; Alvarez, R.; et al. Pim-1 regulates cardiomyocyte survival downstream of Akt. Nat. Med. 2007, 13, 1467– 1475.
149. Mohsin, S.; Khan, M.; Nguyen, J.; Alkatib, M.; Siddiqi, S.; Hariharan, N.; Wallach, K.; Monsanto, M.; Gude, N.; Dembitsky, W.; et al. Rejuvenation of human cardiac progenitor cells with Pim-1 kinase. Circ. Res. 2013, 113, 1169–1179.
150. Mohsin, S.; Khan, M.; Toko, H.; Bailey, B.; Cottage, C.T.; Wallach, K.; Nag, D.; Lee, A.; Siddiqi, S.; Lan, F.; et al. Human cardiac progenitor cells engineered with Pim-I kinase enhance myocardial repair. J. Am. Coll. Cardiol. 2012, 60, 1278–1287.
151. Bhute, V.J.; Bao, X.; Palecek, S.P. Advances in Applications of Metabolomics in Pluripotent Stem Cell Research. Curr. Opin. Chem. Eng. 2017, 15, 36–43.
152. Ezashi, T.; Das, P.; Roberts, R.M. Low O2 tensions and the prevention of differentiation of hES cells. Proc. Natl. Acad. Sci. USA 2005, 102, 4783–4788.
153. Mohyeldin, A.; Garzon-Muvdi, T.; Quinones-Hinojosa, A. Oxygen in stem cell biology: A critical component of the stem cell niche. Cell Stem Cell 2010, 7, 150–161.
154. Cho, Y.M.; Kwon, S.; Pak, Y.K.; Seol, H.W.; Choi, Y.M.; Park, D.J.; Park, K.S.; Lee, H.K. Dynamic changes in mitochondrial biogenesis and antioxidant enzymes during the spontaneous differentiation of human embryonic stem cells. Biochem. Biophys. Res. Commun. 2006, 348, 1472–1478.
155. Facucho-Oliveira, J.M.; Alderson, J.; Spikings, E.C.; Egginton, S.; St John, J.C. Mitochondrial DNA replication during differentiation of murine embryonic stem cells. J. Cell Sci. 2007, 120, 4025–4034.
156. Liu, Y.; Ma, T. Metabolic regulation of mesenchymal stem cell in expansion and therapeutic application. Biotechnol. Prog. 2015, 31, 468–481.
157. Zhang, J.; Nuebel, E.; Daley, G.Q.; Koehler, C.M.; Teitell, M.A. Metabolic regulation in pluripotent stem cells during reprogramming and self-renewal. Cell Stem Cell 2012, 11, 589–595.
158. Kuppusamy, K.T.; Jones, D.C.; Sperber, H.; Madan, A.; Fischer, K.A.; Rodriguez, M.L.; Pabon, L.; Zhu, W.Z.; Tulloch, N.L.; Yang, X.; et al. Let-7 family of microRNA is required for maturation and adult-like metabolism in stem cell-derived cardiomyocytes. Proc. Natl. Acad. Sci. USA 2015, 112, E2785–E2794.
159. Lener, T.; Gimona, M.; Aigner, L.; Borger, V.; Buzas, E.; Camussi, G.; Chaput, N.; Chatterjee, D.; Court, F.A.; Del Portillo, H.A.; et al. Applying extracellular vesicles based therapeutics in clinical trials—An ISEV position paper. J. Extr. Vesicles 2015, 4, 30087.
160. Ratajczak, M.Z.; Ratajczak, J. Extracellular Microvesicles as Game Changers in Better Understanding the Complexity of Cellular Interactions-From Bench to Clinical Applications. Am. J. Med. Sci. 2017, 354, 449– 452.
161. Li, M.; Zeringer, E.; Barta, T.; Schageman, J.; Cheng, A.; Vlassov, A.V. Analysis of the RNA content of the exosomes derived from blood serum and urine and its potential as biomarkers. Phil. Trans. R. Soc. B 2014, 369, 20130502.
162. Iaconetti, C.; Sorrentino, S.; De Rosa, S.; Indolfi, C. Exosomal miRNAs in Heart Disease. Physiology 2016, 31, 16–24.
163. Arslan, F.; Lai, R.C.; Smeets, M.B.; Akeroyd, L.; Choo, A.; Aguor, E.N.; Timmers, L.; van Rijen, H.V.; Doevendans, P.A.; Pasterkamp, G.; et al. Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. Stem Cell Res. 2013, 10, 301–312.
164. Adamiak, M.; Sahoo, S. Exosomes in Myocardial Repair: Advances and Challenges in the Development of Next-Generation Therapeutics. Mol. Ther. J. Am. Soc. Gene Ther. 2018, 26, 1635–1643.
165. Davidson, S.M.; Yellon, D.M. Exosomes and cardioprotection—A critical analysis. Mol. Asp. Med. 2018, 60, 104–114.
166. Gartz, M.; Strande, J.L. Examining the Paracrine Effects of Exosomes in Cardiovascular Disease and Repair. J. Am. Heart Assoc. 2018, 7, e007954.
167. Zhao, Y.; Sun, X.; Cao, W.; Ma, J.; Sun, L.; Qian, H.; Zhu, W.; Xu, W. Exosomes Derived from Human Umbilical Cord Mesenchymal Stem Cells Relieve Acute Myocardial Ischemic Injury. Stem Cells Int. 2015, 2015, 761643.
168. Lai, R.C.; Arslan, F.; Lee, M.M.; Sze, N.S.; Choo, A.; Chen, T.S.; Salto-Tellez, M.; Timmers, L.; Lee, C.N.; El Oakley, R.M.; et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res. 2010, 4, 214–222.
169. Bian, S.; Zhang, L.; Duan, L.; Wang, X.; Min, Y.; Yu, H. Extracellular vesicles derived from human bone marrow mesenchymal stem cells promote angiogenesis in a rat myocardial infarction model. J. Mol. Med. 2014, 92, 387–397.
170. Cui, X.; He, Z.; Liang, Z.; Chen, Z.; Wang, H.; Zhang, J. Exosomes from Adipose-derived Mesenchymal Stem Cells Protect the Myocardium Against Ischemia/Reperfusion Injury Through Wnt/beta-Catenin Signaling Pathway. J. Cardiovasc. Pharmacol. 2017, 70, 225–231.
171. Zhang, Z.; Yang, J.; Yan, W.; Li, Y.; Shen, Z.; Asahara, T. Pretreatment of Cardiac Stem Cells with Exosomes Derived from Mesenchymal Stem Cells Enhances Myocardial Repair. J. Am. Heart Assoc. 2016, 5, e002856.
172. Gallet, R.; Dawkins, J.; Valle, J.; Simsolo, E.; de Couto, G.; Middleton, R.; Tseliou, E.; Luthringer, D.; Kreke, M.; Smith, R.R.; et al. Exosomes secreted by cardiosphere-derived cells reduce scarring, attenuate adverse remodelling, and improve function in acute and chronic porcine myocardial infarction. Eur. Heart J. 2017, 38, 201–211.
173. Schey, K.L.; Luther, J.M.; Rose, K.L. Proteomics characterization of exosome cargo. Methods 2015, 87, 75–82.
174. Kim, H.S.; Choi, D.Y.; Yun, S.J.; Choi, S.M.; Kang, J.W.; Jung, J.W.; Hwang, D.; Kim, K.P.; Kim, D.W. Proteomic analysis of microvesicles derived from human mesenchymal stem cells. J. Proteome Res. 2012, 11, 839–849.
175. Lai, R.C.; Tan, S.S.; Teh, B.J.; Sze, S.K.; Arslan, F.; de Kleijn, D.P.; Choo, A.; Lim, S.K. Proteolytic Potential of the MSC Exosome Proteome: Implications for an Exosome-Mediated Delivery of Therapeutic Proteasome. Int. J. Proteom. 2012, 2012, 971907.
176. Vallabhaneni, K.C.; Penfornis, P.; Dhule, S.; Guillonneau, F.; Adams, K.V.; Mo, Y.Y.; Xu, R.; Liu, Y.; Watabe, K.; Vemuri, M.C.; et al. Extracellular vesicles from bone marrow mesenchymal stem/stromal cells transport tumor regulatory microRNA, proteins, and metabolites. Oncotarget 2015, 6, 4953–4967.
177. Sahoo, S.; Klychko, E.; Thorne, T.; Misener, S.; Schultz, K.M.; Millay, M.; Ito, A.; Liu, T.; Kamide, C.; Agrawal, H.; et al. Exosomes from human CD34(+) stem cells mediate their proangiogenic paracrine activity. Circ. Res. 2011, 109, 724–728.
178. Mocharla, P.; Briand, S.; Giannotti, G.; Dorries, C.; Jakob, P.; Paneni, F.; Luscher, T.; Landmesser, U. AngiomiR-126 expression and secretion from circulating CD34(+) and CD14(+) PBMCs: Role for proangiogenic effects and alterations in type 2 diabetics. Blood 2013, 121, 226–236.
179. Gray, W.D.; French, K.M.; Ghosh-Choudhary, S.; Maxwell, J.T.; Brown, M.E.; Platt, M.O.; Searles, C.D.; Davis, M.E. Identification of therapeutic covariant microRNA clusters in hypoxia-treated cardiac progenitor cell exosomes using systems biology. Circ. Res. 2015, 116, 255–263.
180. Namazi, H.; Mohit, E.; Namazi, I.; Rajabi, S.; Samadian, A.; Hajizadeh-Saffar, E.; Aghdami, N.; Baharvand, H. Exosomes secreted by hypoxic cardiosphere-derived cells enhance tube formation and increase proangiogenic miRNA. J. Cell. Biochem. 2018, 119, 4150–4160.
181. Meng, Y.; Eirin, A.; Zhu, X.Y.; Tang, H.; Chanana, P.; Lerman, A.; Van Wijnen, A.J.; Lerman, L.O. The metabolic syndrome alters the miRNA signature of porcine adipose tissue-derived mesenchymal stem cells. Cytom. Part A 2018, 93, 93–103.
182. Henry, V.J.; Bandrowski, A.E.; Pepin, A.S.; Gonzalez, B.J.; Desfeux, A. OMICtools: An informative directory for multi-omic data analysis. Database J. Biol. Databases Curation 2014, 2014, doi:10.1093/database/bau069.
183. Torre, D.; Krawczuk, P.; Jagodnik, K.M.; Lachmann, A.; Wang, Z.; Wang, L.; Kuleshov, M.V.; Ma'ayan, A. Datasets2Tools, repository and search engine for bioinformatics datasets, tools and canned analyses. Sci. Data 2018, 5, 180023.
184. Manzoni, C.; Kia, D.A.; Vandrovcova, J.; Hardy, J.; Wood, N.W.; Lewis, P.A.; Ferrari, R. Genome, transcriptome and proteome: The rise of omics data and their integration in biomedical sciences. Brief. Bioinform. 2018, 19, 286–302.
185. Vilne, B.; Schunkert, H. Integrating Genes Affecting Coronary Artery Disease in Functional Networks by Multi-OMICs Approach. Front. Cardiovasc. Med. 2018, 5, 89, doi:10.3389/fcvm.2018.00089.
186. Liu, T.; Wu, H.; Wu, S.; Wang, C. Single-Cell Sequencing Technologies for Cardiac Stem Cell Studies. Stem Cells Dev. 2017, 26, 1540–1551.